Access Statistics for Adrian Towse

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
'Macro' Evaluation of the NIHR Oxford Biomedical Research Centre 0 0 2 4 1 4 11 27
Additional Elements of Value for Health Technology Assessment Decisions 1 1 2 16 2 6 16 42
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? 0 0 0 7 0 0 6 31
Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence 0 0 0 18 0 2 9 45
Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies 0 0 0 13 2 2 7 22
Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience 0 0 1 3 0 0 4 10
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? 0 0 2 2 2 2 8 21
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? 0 0 0 0 0 0 1 4
Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold 0 0 4 5 0 0 15 31
Data Governance Arrangements for Real-World Evidence 0 1 2 12 0 1 6 41
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions 0 0 0 1 1 1 5 8
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? 1 2 3 16 1 3 18 47
Exploring the link between health and wealth in decision making 0 0 0 3 0 2 6 19
Four Case Studies to Explore the Added Value of Oxford AHSN 0 0 0 8 0 1 6 16
From Efficacy to Cost-Effectiveness 0 0 0 0 0 0 0 3
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value 4 14 44 109 13 42 125 322
HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers? 0 0 3 18 0 0 11 30
How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? 0 0 0 14 0 0 5 16
How can HTA meet the needs of health system and government decision makers? 0 1 1 13 0 2 16 34
Improving Efficiency and Resource Allocation in Future Cancer Care 0 1 6 19 4 7 36 89
Incentives for New Drugs to Tackle Anti-Microbial Resistance 1 5 10 34 1 7 25 72
Incentives for R&D for New Antimicrobial Drugs 0 0 0 1 0 0 2 7
International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa 1 1 2 6 1 1 7 25
Multi-indication Pricing: Pros, Cons and Applicability to the UK 0 0 0 7 0 2 11 103
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options 0 0 2 7 0 0 4 18
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches 0 0 0 1 1 1 3 5
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement 0 0 0 96 0 0 5 187
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? 0 1 3 4 0 1 4 10
Policy Options for Formulary Development in Middle-income Countries 0 0 0 1 0 0 6 16
Real World Evidence for Coverage Decisions: Opportunities and Challenges 0 0 1 32 0 0 10 74
Reducing Harm to Patients in the National Health Service. Will the Government's Compensation Proposals Help? 0 0 0 1 0 0 4 8
Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry 0 0 1 1 1 2 6 7
Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe 0 0 2 3 0 1 8 19
Review of CRA's Report "Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe" 1 1 3 17 1 2 13 53
Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making 0 0 1 4 0 0 3 19
The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response 2 2 9 20 2 3 18 44
The Expanding Value Footprint of Oncology Treatments 0 0 0 2 0 0 8 14
The Market for Biosimilars: Evolution and Policy Options 0 0 0 2 0 0 2 7
The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? 0 0 1 4 1 1 5 18
Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds 0 0 0 0 0 0 2 5
Transferability of HTA 0 0 2 11 0 1 30 64
Uncertainty and Risk in HTA Decision Making 0 2 4 14 1 7 15 45
Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions 0 0 3 24 0 1 8 45
Using QALYs in Cancer: Review of the Methodological Limitations 0 0 0 1 0 1 2 10
Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context 0 0 1 53 3 3 10 144
What is the Role of HTA for Biosimilars? 0 0 0 0 0 0 6 13
Total Working Papers 11 32 115 627 38 109 528 1,890


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Biosimilars: How Can Payers Get Long-Term Savings? 0 0 0 4 3 4 5 24
European Union Pharmaceutical Markets: A Case for Differential Pricing? 0 0 2 3 2 2 11 21
Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria 0 0 0 8 0 0 1 34
Genetic screening, health care and the insurance industry 0 0 0 1 0 0 4 17
Incentives for R&D for New Antimicrobial Drugs 0 0 0 41 0 1 1 139
Is disease management relevant in Europe: some evidence from the United Kingdom 0 0 0 16 0 0 0 43
Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? 0 1 1 15 1 2 2 36
Medical negligence and the NHS: an economic analysis 0 0 0 0 0 0 3 156
Operationalizing Value-Based Pricing of Medicines 0 0 0 8 2 2 4 44
Orphan drugs policies: a suitable case for treatment 0 1 1 9 0 1 1 31
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement 0 0 0 4 0 1 5 37
The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8 0 0 0 0 0 0 1 6
The desirability and feasibility of economic studies of drugs post-launch 0 0 0 32 0 0 1 99
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation 0 0 0 1 1 6 9 18
Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context 0 0 3 20 3 5 23 103
Total Journal Articles 0 2 7 162 12 24 71 808


Book File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Biosimilars: How Much Entry and Price Competition Will Result? 0 0 0 3 0 0 2 20
Cost-Effectiveness Thresholds: Economic and ethical issues 10 21 37 89 24 55 133 332
Disease Management, the NHS and the Pharmaceutical Industry 0 0 1 2 0 1 10 17
Economic Post-Launch Studies: Matching the Desirable with the Feasible 0 0 0 1 0 1 9 20
Financing Health Care in the UK: A Discussion of NERA's Prototype Model to Replace the NHS 0 0 0 0 0 0 5 10
Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? 0 0 0 1 1 3 9 17
Industrial Policy and the Pharmaceutical Industry 0 0 4 6 0 4 16 31
Influencing Prescribing in a Primary Care Led NHS 0 0 1 1 0 1 7 9
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options 0 0 1 3 2 3 9 23
Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty 0 1 3 5 1 10 34 52
The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way 0 0 0 0 0 0 5 9
The R&D Cost of a New Medicine 8 14 73 169 22 54 242 517
Value of the Pharmaceutical Industry to the UK Economy 0 4 8 11 0 6 20 30
Total Books 18 40 128 291 50 138 501 1,087


Statistics updated 2021-01-03